Medical Technology Stock Letter

For more than 30 years, the Medical Technology Stock Letter (MTSL) has provided independent investment advice based on rigorous analysis of emerging biotechnology companies and a unique perspective on industry fundamentals. MTSL has a proven track record of identifying many of today’s industry leaders well before the consensus of other analysts.

Find out more about the MTSL

Portfolio Updates

View the latest company updates from our recommended portfolio.